ORIC Pharmaceuticals, Inc. Form 8-K Summary
Business context and reporting period
ORIC Pharmaceuticals, Inc. filed a Form 8-K on November 5, 2020, reporting financial results for the fiscal quarter ended September 30, 2020. The filing identifies the company as a Delaware corporation headquartered in South San Francisco, California, with common stock traded on The Nasdaq Global Select Market under the symbol ORIC.
Financial metrics
The filing states that a press release announcing quarterly financial results was issued and furnished as Exhibit 99.1. The provided filing text does not include the press release or clear values for revenue, net loss, cash flow, margins, debt, liquidity, cash balances, or other financial metrics.
Material changes versus the prior comparable period
The provided text does not contain comparative financial results or describe material changes from the prior-year or prior-quarter period.
Guidance, outlook, risks, and unusual items
The provided filing text does not include management guidance, outlook commentary, risk updates, contingencies, or unusual items. The financial-results information is incorporated by reference to Exhibit 99.1, which is not included in the supplied text.
Important facts for investors to verify
- Obtain and review Exhibit 99.1, the November 5, 2020 financial-results press release.
- Verify quarterly revenue, net loss, operating expenses, cash flow, cash and equivalents, and liquidity runway.
- Review any disclosed development-program updates, financing needs, collaboration matters, or clinical and regulatory risks.
- Note that the information in Item 2.02 and Item 9.01 was furnished, not filed, for purposes of Section 18 of the Exchange Act, except as expressly incorporated by reference.